US 12,178,873 B2
High concentration antibody formulations
Timothy David Osslund, Camarillo, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on May 21, 2021, as Appl. No. 17/326,725.
Application 17/326,725 is a continuation of application No. 16/045,928, filed on Jul. 26, 2018.
Application 16/045,928 is a continuation of application No. 15/144,256, filed on May 2, 2016, granted, now 10,064,946.
Application 15/144,256 is a continuation of application No. 13/702,658, granted, now 9,352,043, previously published as PCT/US2011/036062, filed on May 11, 2011.
Claims priority of provisional application 61/334,986, filed on May 14, 2010.
Prior Publication US 2021/0275671 A1, Sep. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 39/00 (2006.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/24 (2006.01); C07K 16/22 (2006.01)
CPC A61K 47/14 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 39/3955 (2013.01); A61K 39/39591 (2013.01); A61K 47/12 (2013.01); A61K 47/24 (2013.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01)] 10 Claims
 
1. A sterile liquid formulation comprising:
(a) an anti-sclerostin immunoglobulin at a concentration of from about 70 mg/mL to about 120 mg/mL, wherein the immunoglobulin comprises a set of 6 CDRS set forth in amino acid sequences SEQ ID NOs: 73-78;
(b) calcium acetate, wherein the calcium acetate comprises calcium at a concentration ranging from about 5 mM to about 15 mM; and acetate at a concentration ranging from about 10 mM to about 90 mM; and
(c) a polyol in an amount ranging from about 4% w/v to about 6% w/v.